Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0494475 (tonic-clonic seizure)
 1,319 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Depakine Labaz in doses from 30 to 1200 mg daily was given to 52 patients in an outpatient clinic. In 13% of cases symptoms of drug intolerance developed and the treatment had to be discontinued. In 45 cases treatment was continued. The drug was given usually to patients refractory to previous drugs, with evidence of organic brain disease. The highest degree of clinical improvement was observed in patients with grand mal seizures and seizures without convulsions. The influence of this treatment of partial complex seizures was slightly smaller. The number of patients treated was too small for evaluation of the effects in partial simple seizures. The total proportion of improved patients was about 60%. In EEG curves normalization of background activity was the most frequent findings, without appearance of rapid activity. In some cases manifestation of focal changes was observed. The favourable effect of Depakine on seizure activity manifested itself in later period of treatment and was slight. The drug had a favourable effect on the wellbeing of patients and had no significant toxic effect in the liver or kidneys.
Neurol Neurochir Pol
PMID:[Preliminary evaluation of Depakine effects in epilepsy]. 37 Jun 75

Benzonal was given to 52 epileptics. In 50 cases the duration of treatment ranged from 3 months to 7 years (mean 18 months) in doses of 100-500 mg daily, in 2 cases it had to be withdrawn after a short-term treatment because of intolerance. In all cases the drug was given together with other anticonvulsants: hydantoin, derivatives, mysodin, Tegretol, pheneturid or Ospolot in place of previously administered phenobarbital. It was found that benzonal reduced significantly the frequency of partial simple seizures (in 6 out of 20 cases) and grand mal seizures (in 24 out of 34 cases), while its action on the partial complex seizures was much weaker (improvement in only 7 out of 20 cases). The drug was usually well tolerated, side effects of greater intensity developed in 2 cases only, transient somnolence was observed in another 6 cases. In EEG records a slight favourable effect was exerted on pathological background activity with absent effect in focal changes and increase of seizure activity. The authors believe that in view of its favourable clinical action and good tolerance the drug may be widely used in properly selected cases of epilepsy.
Neurol Neurochir Pol
PMID:[Clinico-electroencephalographic observations in epileptic patients during long-term treatment with benzonal]. 81 1

The authors studied 286 patients with epilepsy with disease onset past the age of 20 years (176 males, 110 females) from the urban and rural populations. In 57% of cases the aetiology of epilepsy was undetermined. Among the known aetiological factors head trauma accounted for 15.5% of cases, inflammatory processes in the central nervous system for 4.5%, alcoholism for 7%, vascular lesions for 6%, tumours for 5.2%, degenerative and atrophic changes for 1.5%. Over 40% of patients had had attacks for up to 15 years and over 18% for over 20 years. In 80% of cases grand mal seizures occurred, and in 33% of these cases more than 12 attacks occurred annually. Six cases of status epilepticus were observed with 2 deaths. The attacks were precipitated by menstruation, alcohol abuse, infection, stressed, television watching. Among the signs accompanying or following the seizures tongue biting and urination prevailed. Neurological signs were demonstrated in 21% of cases, encephalopathy in 65%, other psychic disturbances in 9.5%. Systematic treatment was received by 75% of the patients (over 80% in urban population), and therapy with multiple drugs was most frequent. Drug-resistant epilepsy was found in 34% of cases. The patients from the rural population had a lower educational level and had more children. About 70% of the patients were in employment.(ABSTRACT TRUNCATED AT 250 WORDS)
Neurol Neurochir Pol
PMID:[Analysis of clinico-social features of epilepsy]. 404 96

The author analysed 124 cases of grand mal seizures in patients aged above 16 years observed for 2 to 15 years finding sporadic tongue or oral mucosa biting in 55.7% of cases, involuntary passing of urine in 49%, simultaneous occurrence of both these signs in 37% defection in 8.1%, ejaculation in 1.6%, conjunctival o cutaneous ecchymoses in 29.8%, and significant traumas in 20.2% (72% of these cases were men). Assuming that these signs occurred as a rule during each attack these per cent proportions were as follows: 17.7%, 15.3%, 9.7%, 2.4%, 0.8%, 10.5% and 2.4% respectively. Most frequently these signs appeared during the first attacks before treatment beginning, during attacks appearing after several years without seizures, after arbitrary stopping of drug taking and as a result of irregular treatment and alcohol drinking. In 14.5% of patients during observation lasting from 10 to 20 years no peri-ictal signs appeared. In a group of young unmarried people these signs were often concealed, while they were exaggerated by a small group applying for disability pension or wanting to have that pension increased. Patients from rural areas seemed to give less attention to these concomitant signs.
Neurol Neurochir Pol
PMID:[Symptoms accompanying epileptic attacks]. 643 40

18 patients (9 females, 9 males) with juvenile myoclonic epilepsy (JME) were studied. Despite a fairly long duration of the disease (from 1 to 34 years--mean 9.5 years) the patients had not been properly diagnosed. In all cases routine serial EEG examinations, 24-hour EEG with Medilog System 9000, and polygraphic Video/EEG/EMG recording were done (Videometry Processor, Glonner). Typical attack triads occurred in 7 cases (39%), grand mal seizures and myoclonic attacks in 10 cases (56%), one patient had only myoclonic seizures. EEG demonstrated already in routine recording occurrence of seizure activity with spike/polyspike-slow wave 3-6 Hz complexes. 24-hour EEG made possible demonstration of these complexes in the remaining 4 cases. Seizure activity during clinical myoclonic seizures were recorded in 8 cases, and during absences in 2 cases. A valuable method was also Video/EEG/EMG recording which showed occurrence of both myoclonic seizures (in 5 cases) and absences (9 cases). Three patients with absences were not aware of their seizures. In 8 patients EEG findings demonstrated focal abnormalities which contributed to previous diagnostic errors. The described clinical and electrophysiological features met fully the diagnostic criteria of JME. In the Polish literature this is the first report on such a large groups of JME cases. Attention is called to diagnostic difficulties due to poor knowledge of this disease and its manifestations which leads to inaccurate history taking. Another cause is non-availability of full neurophysiological diagnostic facilities in many centers.
Neurol Neurochir Pol
PMID:[Clinical-electrophysiological pattern of juvenile myoclonic epilepsy]. 858 94

On the case of 27 old woman with clinical symptoms of acute abdomen, severe electrolyte disturbances and attacks of grand mal seizures, different clinical masks and actual treatment guidelines of acute intermittent porphyria are presented. Among laboratory methods detecting precursors of hem in the urine, high-performance liquid chromatography (HPLC) as the most sensitive and specific method is recommended. Proper prophylaxis against new episodes of acute intermittent porphyria as well as long lasting ambulatory care of the patient are emphasized. Special attention should be paid to all close relatives of the patient, who need to be send to specialistic laboratories for exclusion of enzymatic defects of hem synthesis.
Pol Merkur Lekarski 1998 Nov
PMID:[Acute intermittent porphyria: actual problems of clinical and laboratory diagnosis]. 1010 5

The efficacy and safety of vigabatrin (VGB) has been extensively evaluated in preclinical and clinical studies but level of effectiveness in different type of seizures has yet to be established. The aim of our study is the prospective evaluation of anticonvulsant efficacy and toxicity of VGB. This long-term observation mainly focusing on efficacy of VGB in partial vs. secondarily generalized seizures were considered separately. In our study the criterion of drug resistance is occurrence per month of at least 1 tonic-clonic seizure or at least 2 complex partial seizures in 3 following months. The studies are based on 73 patients (39 F and 34 M), with average age of 26 years. After two weeks of treatment with sabril the drug was withdrawn in 5 patients because of side effects. The period of observation was 12 months. In group I--from total of 73 patients with partial seizures (including secondarily generalized)--31 (42%) of patients suffered only from partial seizures. Complex partial seizures occurred in 18 of patients; in this group were also 13 patients with simple partial seizures. Group II consisted of 42 patients (58%) who suffered from secondarily generalized tonic-clonic seizures. Number of seizures in group of patients with tonic-clonic seizures was from 1 to 16 per month (average 3.4) and in group of patients with complex partial seizures was from 1 to 70 per month (average 13.29). After titration period, Vigabatrin was given in doses of 500 to 3500 mg daily. Mean monthly fit frequency was calculated for over 3 months prior to the addition of vigabatrin and 12 months of therapy at the patient's maximum dose. Monthly fit frequency expressed as mean +/- standard error of the mean, and this statistical significance was determined using MANOVA for repeated measurement. Average monthly fit frequency of partial seizures has been reduced from 13.29 to 6.96 (p < 0.0001) and of generalized seizures from 3.38 to 1.38 (p < 0.0001). The percentage of patients achieving an increase of at least 75%--(Ratio < -0.6)--of seizures was greater in generalized seizures (27.3) than in partial ones (21.3). VGB is effective and well tolerated in refractory patients requiring add-on antiepileptic treatment and it has shown efficacy both in therapy of refractory partial seizures as well of secondarily generalized ones.
Neurol Neurochir Pol 2000
PMID:[Clinical analysis of the effectiveness and safety of vigabatrin]. 1076 57

Carbatrol (CBR) is a new multiple-unit, sustained-release dosage form of carbamazepine (CBZ) developed by Pharmavene. We present a multicenter, outpatient, randomized, double-blind parallel group study (No PI 101) carried out in two centers in Poland. CBR was evaluated in 47 patients with uncontrolled partial onset seizures. During the 28-day baseline period, patients were required to have at least two seizures and to take CBZ at a therapeutic level, a second antiepileptic drug was allowed but not valproic acid (VPA ). Patients were randomized to VPA or to CBR (dosages 800, 1200, 1600 mg/day). Criteria for escape relative to baseline were: two-fold increase in monthly seizure frequency, two-fold increase in 2-day seizure frequency, two-fold increase in weekly seizure frequency, single generalized tonic-clonic seizure (GTCs) if none occurred during baseline or prolongation of GTCs. The primary efficacy variable was the number of patients escaping in each treatment group. Nineteen patients on VPAand 7 on CBR met escape criteria. CBR adverse experiences were all mild or moderate in severity. CBR therapy was effective in the treatment of partial complex seizures with or without generalization.
Pol J Pharmacol
PMID:A multicenter, placebo-controlled, double-blind study of efficacy of a new form of carbamazepine (Carbatrol) in refractory epileptic patients. 1515 70